CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 106 enrolled
Drug / intervention
Glutaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01414244
NCT01414244Phase 2Completed
CompareCT.gov

Randomized, Placebo-Controlled Trial of Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

Tulane University·interventional·Posted Aug 11, 2011·Updated Aug 9, 2017

In Brief

A Phase 2 clinical trial evaluating Glutamine for Diarrhea-Predominant Irritable Bowel Syndrome. Completed, enrolled 106 participants across 1 site.

Detailed Summary

New and effective treatments are needed for patients with post-infectious irritable bowel syndrome (PI-IBS). We conducted a randomized, placebo-controlled trial to assess the efficacy and safety of glutamine, an abundant amino acid in the body and the principal fuel for enterocytes, in patients who developed diarrhea-predominant irritable bowel syndrome with increased intestinal permeability following an enteric infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiarrhea-Predominant Irritable Bowel Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 11, 2011
Enrollment StartNov 1, 2010
Primary CompletionDec 30, 2015
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 14.9 years ago

Interventions

Glutaminedrug

Drug